These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
154 related articles for article (PubMed ID: 38591640)
1. Antibiotics for the treatment of lower respiratory tract infections in children with neurodisability: Systematic review. Marpole RM; Bowen AC; Langdon K; Wilson AC; Gibson N Acta Paediatr; 2024 Jun; 113(6):1203-1208. PubMed ID: 38591640 [TBL] [Abstract][Full Text] [Related]
2. Azithromycin for acute lower respiratory tract infections. Laopaiboon M; Panpanich R; Swa Mya K Cochrane Database Syst Rev; 2015 Mar; 2015(3):CD001954. PubMed ID: 25749735 [TBL] [Abstract][Full Text] [Related]
11. In-vitro activity of imipenem/relebactam and key β-lactam agents against Gram-negative bacilli isolated from lower respiratory tract infection samples of intensive care unit patients - SMART Surveillance United States 2015-2017. Karlowsky JA; Lob SH; Kazmierczak KM; Young K; Motyl MR; Sahm DF Int J Antimicrob Agents; 2020 Jan; 55(1):105841. PubMed ID: 31704217 [TBL] [Abstract][Full Text] [Related]
12. Antibiotics for community-acquired lower respiratory tract infections secondary to Mycoplasma pneumoniae in children. Gardiner SJ; Gavranich JB; Chang AB Cochrane Database Syst Rev; 2015 Jan; 1(1):CD004875. PubMed ID: 25566754 [TBL] [Abstract][Full Text] [Related]
13. Antibiotics for community acquired lower respiratory tract infections (LRTI) secondary to Mycoplasma pneumoniae in children. Gavranich JB; Chang AB Cochrane Database Syst Rev; 2005 Jul; (3):CD004875. PubMed ID: 16034954 [TBL] [Abstract][Full Text] [Related]
14. Pseudomonas aeruginosa infection in respiratory samples in children with neurodisability-to treat or not to treat? Gregson E; Thomas L; Elphick HE Eur J Pediatr; 2021 Sep; 180(9):2897-2905. PubMed ID: 33822245 [TBL] [Abstract][Full Text] [Related]
15. Antibiotics for community-acquired lower respiratory tract infections secondary to Mycoplasma pneumoniae in children. Mulholland S; Gavranich JB; Chang AB Cochrane Database Syst Rev; 2010 Jul; (7):CD004875. PubMed ID: 20614439 [TBL] [Abstract][Full Text] [Related]
16. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. Schuetz P; Müller B; Christ-Crain M; Stolz D; Tamm M; Bouadma L; Luyt CE; Wolff M; Chastre J; Tubach F; Kristoffersen KB; Burkhardt O; Welte T; Schroeder S; Nobre V; Wei L; Bhatnagar N; Bucher HC; Briel M Cochrane Database Syst Rev; 2012 Sep; 2012(9):CD007498. PubMed ID: 22972110 [TBL] [Abstract][Full Text] [Related]
17. Piperacillin/tazobactam: a pharmacoeconomic review of its use in moderate to severe bacterial infections. Young M; Plosker GL Pharmacoeconomics; 2001; 19(11):1135-75. PubMed ID: 11735679 [TBL] [Abstract][Full Text] [Related]
18. In vitro activity of ceftolozane/tazobactam against Gram-negative isolates collected from ICU patients with lower respiratory tract infections in seven Asian countries-SMART 2017-2019. Lob SH; Kazmierczak KM; Chen WT; Siddiqui F; DeRyke CA; Young K; Motyl MR; Sahm DF J Glob Antimicrob Resist; 2022 Jun; 29():527-533. PubMed ID: 34896336 [TBL] [Abstract][Full Text] [Related]
19. The Retrospective Cohort of Extended-Infusion Piperacillin-Tazobactam (RECEIPT) study: a multicenter study. Yost RJ; Cappelletty DM; Pharmacotherapy; 2011 Aug; 31(8):767-75. PubMed ID: 21923603 [TBL] [Abstract][Full Text] [Related]